SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending due to a significant after-hours drop following its earnings report, despite an EPS beat, as revenue concerns and increased capital expenditures spooked investors. The community is actively discussing the implications of the results on Oracle's debt and future growth, particularly in the AI space, with some questioning the company's long-term viability while others see a buying opportunity amidst the volatility.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a high percentage gain, leading to speculation about a potential short squeeze, with community members actively watching for further upward momentum and comparing it to similar past runners. Discussions revolve around its low float and potential for significant volatility, as well as the possibility of after-hours action. Some traders are warning of a potential pump and dump.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war for Warner Bros. Discovery (WBD), with community discussions focused on whether Netflix will increase its offer or walk away; a Paramount bid could allow Netflix to collect a termination fee. Some investors worry about the debt Netflix would incur if it wins the bidding war, while others speculate about political motivations affecting the deal.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss the company's upcoming earnings report and its potential in the AI landscape. While some express concerns about competition from AI and other platforms, others highlight Adobe's established position and potential for growth, emphasizing its AI integration and buyback program.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending following the approval of a Designated Contract Market (DCM) license from the CFTC, allowing it to launch prediction markets. The community is discussing the potential for a short squeeze and comparing Gemini's prospects to other players in the prediction market space. Some investors see this as a bullish catalyst, while others express skepticism given GEMI's performance since its IPO.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending as traders highlight its undervalued status in the digital infrastructure space, citing its expansion into AI GPU workloads and growing power capacity as differentiators from standard miners. The stock's tight float is a key talking point, with traders anticipating significant price movement from upcoming catalysts such as operational updates and potential new contracts from an upcoming conference. Bullish sentiment is building, as traders express that MIGI is primed for a squeeze and potential rally.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to a U.S. patent allowance for its EVM301 series, sparking discussions of a potential short squeeze given the stock's low float; community members are weighing the IP news against the company's history of dilution. Some traders are also speculating about a potential settlement with AbbVie, which could boost the stock.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys ($SNPS) is trending after a significant investment from Nvidia, fueling optimism around AI-driven chip design and engineering; the community is closely watching whether this partnership marks a turning point for the stock, which experienced a notable drop after its recent earnings report, and many are hoping this investment will lead to new all-time highs. Some investors are also closely monitoring the impact of potential restrictions on semiconductor software exports to China, a key market for Synopsys.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to strong earnings, a recent acquisition, and increased price targets from analysts, driving positive after-hours movement. The community is excited about the company's growth, particularly its partnerships and expanding presence in the defense and intelligence sectors. Discussions revolve around the potential for all-time highs and a continued bullish outlook for this space-based data provider.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid a potential bidding war between Netflix and Paramount, with the latter launching a hostile takeover bid. Community discussions revolve around the implications of each deal, the likelihood of regulatory approval, and potential counteroffers. Investors are weighing the impact on the broader entertainment sector, particularly for involved companies like NFLX and PSKY.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One...

Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen upgraded Context Therapeutics to a "sell" rating in a report on Saturday...

Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday...

Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts...

Shares of Context Therapeutics Inc. rose over&nbsp;7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.&nbsp;The brokerage's target implies a near quadrupling from the stock's previous close and has fueled bullish sentiment among retail investors.In its research note, JMP highlighted Context's focus on developing next-generation T-cell-engaged bispecific antibody therapies for solid tumors.&nbsp;The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which the analyst described as "innovative."&nbsp;JMP also praised the management team's business development acumen in assembling a pipeline that it believes is “worth more than the sum of its parts.”Retail chatter on Stocktwits mirrored the analyst's enthusiasm, with one user predicting a move to $6 and another noting the stock could "come back in a hurry" after a period of limited news flow.<stembedurl>https://stocktwits.com/Leonkika/message/599089608</stembedurl><stembedurl>https://stocktwits.com/claybridge/message/598957638</stembedurl>Context Therapeutics' lead program, CTIM-76, is poised to enter clinical trials soon.&nbsp;According to D. Boral Capital, which issued a ‘Buy’ rating and a $9 price target in November, CTIM-76 targets Claudin 6, a tumor marker broadly expressed in solid tumors like gynecologic and testicular cancers but largely absent in healthy adult tissues.&nbsp;This specificity makes it a promising therapeutic target, the brokerage said.Context’s stock has lost over 8% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”

Equity

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”


Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 26, 2024 USA News...

Context Therapeutics submits IND application for CTIM-76

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ( Context or the Company ) (Nasdaq: CNTX), a...

Context Therapeutics Advances Cancer Trial with FDA Submission

Context Therapeutics (CNTX) has provided an update. Context Therapeutics Inc. has announced the submission of an IND application to the FDA for a P...

Context Therapeutics (NASDAQ:CNTX) Price Target Cut to $4.00

Context Therapeutics (NASDAQ:CNTX  Free Report) had its target price lowered by HC Wainwright from $5.00 to $4.00 in a research report sent to investors on Thursday, Benzinga reports. HC...

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Context Therapeutics Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

CNTX
Context Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CNTX News

CNTXContext Therapeutics Inc